Founded in 1979, after more than 40 years of development, CMEF has become a global comprehensive medical exhibition covering the entire industry chain of medical devices. At this expo, nearly 4,000 brand enterprises from all over the world will gather strongly in Shenzhen, setting off the climax of industry development in 2023 and injecting new momentum for high-quality development into the global medical device industry.

Booth Number: 13E39

Welcome new and old friends to visit the booth to communicate.

On October 28th, we will also share topics in the exhibition area and interact with the guests in the game, welcome you to participate in the booth.

At this exhibition, Minkang's scientific and technological innovation achievements will meet with you, and more product details please visit the booth to understand.

During the exhibition, senior technical experts of Minkang will bring a special lecture on "Introduction and Prospect of Continuous Glucose Monitoring Technology Platform", and conduct in-depth exchanges with you on the new exploration and attempt of human diabetes treatment. Welcome friends to come. Lecture time: October 28, 10:00, 14:00.

Founded in 2010, Minkang is a national high-tech enterprise specializing in the research and development, production and sales of rapid detection products for chronic diseases. At present, it has nearly 100 core R & D personnel, forming a domestic leading electrochemical, photochemical, colloidal gold, immunofluorescence four major technical systems. Single-atom catalytic process has reached the international first-class level, the full range of products cover blood sugar, blood lipids, blood ketones, uric acid, glycated hemoglobin and other indicators detection, and has started from continuous glucose monitoring (CGMs) to continuous multi-index monitoring (CXMs) and artificial pancreas continuous exploration.

The company adheres to the vision of building a "chronic disease management ecology that understands you", bases itself on the blood glucose monitoring industry, promotes the establishment of a closed-loop chronic disease management ecology from real-time monitoring to data analysis to remote intervention, helps the national medical reform and graded diagnosis and treatment strategy, and moves towards the goal of China's exemplary benchmarking enterprise in the global chronic disease management industry, and becomes a pioneer in China's closed-loop solutions for chronic diseases. In addition, Minkang actively expands overseas markets, and its business has spread to more than 30 countries and regions around the world.